I am interested in researching ways to improve the care of children with complex congenital heart disease including those who require extracorporeal life support.
Pediatric Critical Care
M.D., University of Massachusetts Medical School, Worcester, Massachusetts, 1993
Ph.D., City University of New York, New York, New York, 1990
B.A./B.S., University of Rochester, Rochester, New York, 1984
Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 1996
Children’s Hospital and Regional Medical Center, Seattle, Washington, 2004
American Board of Pediatrics, Critical Care Medicine, 2006
American Board of Pediatrics, General Pediatrics, 2010
American Academy of Pediatrics
California Thoracic Society
Massachusetts Medical Society
Society for Critical Care Medicine
Honors and Awards
Pasadena Top Doctors, 2010
Sigma Xi, Mt. Sinai School of Medicine Chapter, 1988
Select Recent Publications
Doki T, Mello M, Mock D, Evans JM and Kearns-Jonker, M., Intragraft gene expression profile associated with the induction of tolerance, BMC Immunol. 2008 Feb 11;9:5.
Evans JM , Doki T, Fischer-Lougheed J, Davicioni E and Kearns-Jonker M, WTC06: Expression Changes in Tolerant Cardiac Allografts after Gene Therapy with a Lentiviral Vector Expressing ?1,3 Galactosyltransferase, Transplantation Proceedings, 38:3172-3180, 2006.
Evans J and Cohen G, Catecholamine Uptake Inhibitors Elevate 6-Hydroxydopamine in Brain After Administration of 6-hydroxydopa. Eur J Pharmacol, 232:241-245, 1993.
Cohen G and Evans J, Vesicular Binding of 6-Hydroxydopamine Does Not Explain the Resistance of Dopamine Nerve Terminals to 6-Hydroxydopa. Neurodegeneration, 1:241-246, 1992.
Evans JM and Cohen G, Can Trace Amounts of Neurotoxins Destroy Dopamine Neurons? Neurochemistry International, 15:127-129, 1989.
Evans JM and Cohen G, Studies on the Formation of 6-Hydroxydopamine in Brain After the Administration of 2,4,5-Trihydroxyphenylalanine (6-HydroxyDOPA). J. Neurochem, 52:1461-1467, 1989.